Nosebleeds in hereditary hemorrhagic telangiectasia: Development of a patient-completed daily eDiary

Marci Clark, Pamela Berry, Susan Martin, Nimanee Harris, Dennis Sprecher, Scott Olitsky, Jeffrey B Hoag, Marci Clark, Pamela Berry, Susan Martin, Nimanee Harris, Dennis Sprecher, Scott Olitsky, Jeffrey B Hoag

Abstract

Objective: A prospective, qualitative study was conducted to develop a patient-reported outcome measure (PROM) for daily administration via electronic diary (eDiary) to assess the severity of nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), in accordance with Food and Drug Administration (FDA) PROM guidance criteria.

Methods: Three expert clinicians who treat patients with HHT provided input during instrument development, which comprised: 1) Peer-reviewed literature and instrument review; 2) Development of draft Nosebleed Diary items; 3a) Three rounds of qualitative interviews (two with a paper-based diary, one with an eDiary) with patients with documented severe epistaxis related to HHT, for concept elicitation and cognitive debriefing; 3b) Face validity and translatability assessment; 3c) Patient evaluation of the usability and acceptability of the eDiary device; and 4) Preparation of the final Nosebleed eDiary and conceptual framework.

Results: No existing instruments were identified that evaluate HHT-related nosebleed severity daily and meet FDA PROM guidance criteria. Frequency, duration, and/or speed of flow (i.e., intensity) were reported by most participants with HHT when asked to describe their nosebleed severity. The Nosebleed eDiary was refined based on 17 patient interviews, clinical expert input and the face validity and translatability assessment. The final four-item eDiary was acceptable to patients with HHT.

Conclusion: The Nosebleed eDiary is "fit for purpose" to assess the severity of HHT-related nosebleeds, and has established face and content validity. Further adaptation may be required for use in mild or moderate HHT populations. Psychometric testing to evaluate construct validity and reliability are recommended next steps.

Level of evidence: 2c "Outcomes research".

Keywords: Epistaxis; Osler‐Weber‐Rendu; hereditary hemorrhagic telangiectasia; nosebleed; patient‐reported outcome.

Figures

Figure 1
Figure 1
Overview of the Nosebleed eDiary development process.
Figure 2
Figure 2
Final version of the Nosebleed eDiary.
Figure 3
Figure 3
Nosebleed eDiary conceptual framework.

References

    1. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010;24:203–219.
    1. Faughnan ME, Palda VA, Garcia‐Tsao G et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48:73–87.
    1. Zarrabeitia R, Farinas‐Alvarez C, Santibanez M, et al. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT). Health Qual Life Outcomes 2017;15:19.
    1. Merlo CA, Yin LX, Hoag JB, Mitchell SE, Reh DD. The effects of epistaxis on health‐related quality of life in patients with hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol 2014;4:921–925.
    1. Loaec M, Moriniere S, Hitier M, Ferrant O, Plauchu H, Babin E. Psychosocial quality of life in hereditary haemorrhagic telangiectasia patients. Rhinology 2011;49:164–167.
    1. Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabba C. Health‐related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu‐Osler‐Weber disease. Qual Life Res 2004;13:1715–1723.
    1. Lennox PA, Hitchings AE, Lund VJ, Howard DJ. The SF‐36 health status questionnaire in assessing patients with epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19:71–74.
    1. Geisthoff UW, Heckmann K, D'Amelio R, et al. Health‐related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 2007;136:726–733; discussion 734–725.
    1. Jorgensen G, Lange B, Wanscher JH, Kjeldsen AD. Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2011;268:1765–1770.
    1. Geirdal AO, Dheyauldeen S, Bachmann‐Harildstad G, Heimdal K. Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: a population based study. Am J Med Genet A 2012;158A:1269–1278.
    1. Ingrand I, Ingrand P, Gilbert‐Dussardier B, et al. Altered quality of life in Rendu‐Osler‐Weber disease related to recurrent epistaxis. Rhinology 2011;49:155–162.
    1. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010;120:838–843.
    1. Food and Drug Administration (FDA) . Guidance for Industry. Patient‐Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: . Accessed August 2017.
    1. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity—establishing and reporting the evidence in newly developed patient‐reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1—eliciting concepts for a new PRO instrument. Value Health 2011;14:967–977.
    1. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity—establishing and reporting the evidence in newly developed patient‐reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health 2011;14:978–988.
    1. Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia‐associated epistaxis. Laryngoscope 2011;121:636–638.
    1. Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012;122:495–497.
    1. Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C. Bevacizumab nasal spray: noninvasive treatment of epistaxis in patients with Rendu‐Osler disease. Laryngoscope 2012;122:953–955.
    1. Dheyauldeen S, Ostertun Geirdal A, Osnes T, Vartdal LS, Dollner R. Bevacizumab in hereditary hemorrhagic telangiectasia‐associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope 2012;122:1210–1214.
    1. Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double‐blind, randomized, placebo‐controlled trial. Head Neck 2015;37:783–787.
    1. Al‐Deen S, Bachmann‐Harildstad G. A grading scale for epistaxis in hereditary haemorrhagic teleangectasia. Rhinology 2008;46:281–284.
    1. Ichimura K, Kikuchi H, Imayoshi S, Yamauchi T, Ishikawa K. Are patients with severe epistaxis caused by hereditary hemorrhagic telangiectasia satisfied with nostril closure surgery? Auris Nasus Larynx 2012;39:59–64.
    1. Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999;13:319–322.
    1. Hitchings AE, Lennox PA, Lund VJ, Howard DJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005;19:75–78.
    1. Bergler W, Sadick H, Gotte K, Riedel F, Hormann K. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002;111:222–228.
    1. Folz BJ, Tennie J, Lippert BM, Werner JA. Natural history and control of epistaxis in a group of German patients with Rendu‐Osler‐Weber disease. Rhinology 2005;43:40–46.
    1. Rebeiz EE, Bryan DJ, Ehrlichman RJ, Shapshay SM. Surgical management of life‐threatening epistaxis in Osler‐Weber‐Rendu disease. Ann Plast Surg 1995;35:208–213.
    1. Pagella F, Semino L, Olivieri C, et al. Treatment of epistaxis in hereditary hemorrhagic telangiectasia patients by argon plasma coagulation with local anesthesia. Am J Rhinol 2006;20:421–425.
    1. de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ. The effect of N‐acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009;47:85–88.
    1. Dupuis‐Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307:948–955.
    1. Braak SJ, de Witt CA, Disch FJ, Overtoom TT, Westermann JJ. Percutaneous embolization on hereditary hemorrhagic telangiectasia patients with severe epistaxis. Rhinology 2009;47:166–171.
    1. Fernandez LA, Garrido‐Martin EM, Sanz‐Rodriguez F, et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK‐1/endoglin pathway in endothelial cells. Thromb Haemost 2007;97:254–262.
    1. Sadick H, Naim R, Oulmi J, Hormann K, Bergler W. Plasma surgery and topical estriol: effects on the nasal mucosa and long‐term results in patients with Osler's disease. Otolaryngol Head Neck Surg 2003;129:233–238.
    1. Patrick DL, Burke LB, Powers JH, et al. Patient‐reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007;10(Suppl 2):S125–S137.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren